Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

HCV infection ups risk of gallstones in patients with chronic liver disease

31 Mar 2018
Those with a history of gallstone disease have a 23% increased risk for coronary heart disease.

In patients with chronic liver disease (CLD), concurrent hepatitis C virus (HCV) infection appears to increase the risk of developing gallstones, a recent China study has shown.

Outcomes in 267 CLD patients with gallstones (median age 61 years; 42.7 percent male) were compared with outcomes in 1,015 CLD patients without gallstones (controls; median age 56 years; 43.6 percent male). Logistic regression analysis was used to calculate for the odds ratios [ORs] of the comparisons.

Multivariable adjusted analysis showed that participants with liver cirrhosis had a significantly higher risk of gallstones than those without cirrhosis (adjusted OR, 2.343; 95 percent CI, 1.710–3.211; p<0.001). The likelihood of developing gallstones was similarly higher in those with HCV-related vs hepatitis B-related CLD (adjusted OR, 1.582; 1.066–2.347; p=0.023).

Age also appeared to be a significant factor, with those 60 years of age being at elevated risks of gallstones relative to their younger counterparts (adjusted OR, 1.848; 1.378–2.477; p<0.001).

Researchers then restricted analysis to the CLD patients with liver cirrhosis. In this subpopulation, HCV-related CLD (adjusted OR, 1.601; 1.063–2.413; p=0.024) and age 60 years (adjusted OR, 1.712; 1.181–2.481; p=0.005) remained as significant risk factors for gallstone development. On the other hand, cirrhosis severity was unrelated to gallstone development, regardless of age.

“[T]he risk of gallstone development in Chinese CLD patients was significantly associated with the occurrence of liver cirrhosis, older age and HCV infection. Furthermore, patients infected with HCV formed more gallstones than did patients infected with HBV,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.